SUMO4 gene and methods of use for type 1 diabetes
View Patent ↗Novel nucleic acids associated with Type 1 diabetes. Also provided are polypeptides encoded by the nucleic acids associated with T1D. The invention also provides methods for facilitating the diagnosis or pre-diagnosis of T1D through the use of such nucleic acids and polypeptides. This invention further provides compositions for the treatment of Type 1 diabetes.
1. An isolated nucleic acid, wherein the nucleic acid comprises a polynucleotide selected from the group consisting of:
a) a polynucleotide as defined in SEQ ID NO: 1;
b) a polynucleotide as defined in SEQ ID NO: 3;
c) a polynucleotide encoding a polypeptide as defined in SEQ ID NO: 2;
d) a polynucleotide encoding a polypeptide as defined in SEQ ID NO: 4;
e) a polynucleotide encoding a polypeptide having at least 99% sequence identity with a polypeptide as defined in SEQ ID NO: 2 or SEQ ID NO: 4 and wherein the polypeptide interacts with IκBα;
f) a polynucleotide complementary to a full-length polynucleotide of any one of a) through e) above.
2. The isolated nucleic acid of claim 1 , wherein the nucleic acid comprises a polynucleotide as defined in SEQ ID NO:1.
3. The isolated nucleic acid of claim 1 , wherein the nucleic acid comprises a polynucleotide as defined in SEQ ID NO:3.
4. The isolated nucleic acid of claim 1 , wherein the nucleic acid comprises a polynucleotide encoding a polypeptide as defined in SEQ ID NO:2.
5. The isolated nucleic acid of claim 1 , wherein the nucleic acid comprises a polynucleotide encoding a polypeptide as defined in SEQ ID NO:4.
6. The isolated nucleic acid of claim 1 , wherein the nucleic acid comprises a polynucleotide encoding a polypeptide having at least 99% sequence identity with a polypeptide as defined in SEQ ID NO:2 or SEQ ID NO:4.
7. The isolated nucleic acid of claim 1 , wherein the nucleic acid encodes a polypeptide that interacts with IκBα.
8. A method for facilitating the diagnosis or pre-diagnosis of Type 1 diabetes in an individual having or at risk of having an increased likelihood for developing Type 1 diabetes comprising:
a) obtaining an isolated nucleic acid sample from the individual where the isolated nucleic acid sample comprises SUMO4 polynucleotide defined in SEQ ID NO: 1 or SEQ ID NO: 3, a SUMO4 polynucleotide that encodes a polypeptide as defined in SEQ ID NO: 2 or SEQ ID NO: 4, or a SUMO4 polynucleotide encoding a polypeptide having at least 99% sequence identity with a polypeptide as defined in SEQ ID NO: 2 or SEQ ID NO: 4; and
b) determining the nucleotide present in the SUMO4 polynucleotide from the isolated nucleic acid sample that corresponds to position 163 of a SUMO4, wherein the presence of a guanine at said position is indicative of a diagnosis of Type 1 diabetes or increased likelihood of Type 1 diabetes in the individual as compared with an individual have an adenine at said position.
9. The method of claim 8 , wherein said method comprises the use of an oligonucleotide probe that detects a mutation in the SUMO4 gene at position 163 of the SUMO4 gene from adenine to guanine.
10. The method of claim 8 , wherein said method comprises the use of an oligonucleotide primer selected from the group consisting of
a) a polynucleotide sequence as defined in SEQ ID NO:7;
b) a polynucleotide sequence as defined in SEQ ID NO:8; and
c) a polynucleotide complimentary to a full length polynucleotide sequence of a) or b) above.